Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Pathologic Complete Response × Radiation × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 70 Prostatic Neoplasms 52 Breast Neoplasms 45 Esophageal Neoplasms 42 Carcinoma, Non-Small-Cell Lung 42 Rectal Neoplasms 36 Lung Neoplasms 35 Gliosarcoma 30 Squamous Cell Carcinoma of Head and Neck 28 Head and Neck Neoplasms 28 Uterine Cervical Neoplasms 26 Pancreatic Neoplasms 26 Brain Neoplasms 26 Neoplasm Metastasis 21 Neoplasms 19 Glioma 18 Esophageal Squamous Cell Carcinoma 18 Sarcoma 17 Melanoma 17 Oropharyngeal Neoplasms 16 Astrocytoma 15 Adenocarcinoma Of Esophagus 14 Stomach Neoplasms 12 Carcinoma, Squamous Cell 12 Urinary Bladder Neoplasms 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Lymphoma, Follicular 10 Central Nervous System Neoplasms 10 Endometrial Neoplasms 9 Lymphoma, B-Cell, Marginal Zone 8

Interventions

Trastuzumab 6 Carboplatin 6 Docetaxel 5 Paclitaxel 4 Oxaliplatin 4 Fluorouracil 4 Cytarabine 4 Cyclophosphamide 4 Azacitidine 4 pertuzumab 3 pembrolizumab 3 Radiotherapy 3 Epirubicin 3 Cisplatin 3 Chemoradiotherapy 3 Capecitabine 3 venetoclax 2 sargramostim 2 olaparib 2 durvalumab 2 cc-486 2 Surgical Procedures, Operative 2 Standard of Care 2 Pemetrexed 2 Observation 2 Monatide (IMS 3015) 2 Metformin 2 Leucovorin 2 Irinotecan 2 Immunotherapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡